Navigation Links
Amgen's First Quarter 2009 Adjusted Earnings Per Share Decreased 4 Percent to $1.08
Date:4/23/2009

for the year ended Dec. 31, 2008, and in our periodic reports on Form 10-Q and Form 8-K. Amgen is providing this information as of the date of this news release and does not undertake any obligation to update any forward-looking statements contained in this document as a result of new information, future events or otherwise.

No forward-looking statement can be guaranteed and actual results may differ materially from those we project. The Company's results may be affected by our ability to successfully market both new and existing products domestically and internationally, clinical and regulatory developments (domestic or foreign) involving current and future products, sales growth of recently launched products, competition from other products (domestic or foreign) and difficulties or delays in manufacturing our products. In addition, sales of our products are affected by reimbursement policies imposed by third-party payors, including governments, private insurance plans and managed care providers and may be affected by regulatory, clinical and guideline developments and domestic and international trends toward managed care and health care cost containment as well as U.S. legislation affecting pharmaceutical pricing and reimbursement. Government and others' regulations and reimbursement policies may affect the development, usage and pricing of our products. Furthermore, our research, testing, pricing, marketing and other operations are subject to extensive regulation by domestic and foreign government regulatory authorities. We or others could identify safety, side effects or manufacturing problems with our products after they are on the market. Our business may be impacted by government investigations, litigation and product liability claims. Further, while we routinely obtain patents for our products and technology, the protection offered by our patents and patent applications may be challenged, invalidated or circumvented by our competit
'/>"/>

SOURCE Amgen
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22

Related medicine news :

1. First biomarker discovered that predicts prostate cancer outcome
2. FDA Approves First Anti-Psychotic for Kids
3. Single-incision belly-button surgery to remove kidney performed first at UT Southwestern
4. First study examines newly-licensed RN work attitudes and intentions
5. Glades General Hospital First in Palm Beach County to Provide On-Site Electronic Birth Registration
6. UHW Announces: Antelope Valley Hospital Caregivers and Board Vote to Ratify First Union Contract With SEIU UHW-West
7. Father and Daughter From Tanzania Receive Their First Medical Examination in Newport Beach
8. High and mighty: first common height gene identified by researchers behind obesity gene finding
9. APA Comments on FDAs First Approval of Medication to Treat Pediatric Schizophrenia and Bipolar Disorder
10. TriWest Creates First-of-its-Kind Partnership to Offer Military Leaders With Grief Support Program
11. Watson Receives First FDA Approval for Manufacturing Product at Its Goa, India Facility
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2015)... ... July 30, 2015 , ... After a three year trial designed to study ... known as the “bionic eye,” researchers have determined the trial to be a success, ... facing or already affected by complete vision loss as a result of Retinitis pigmentosa. ...
(Date:7/30/2015)... ... 2015 , ... At the presentation of the 2015 Annual Meeting of the American Academy ... by the Journal of Arthroplasty pertaining to how soon after undergoing hip replacement surgery ... the study confirm what Santa Rosa Orthopaedics (SRO) surgeon Nathan Ehmer D.O ...
(Date:7/30/2015)... NY (PRWEB) , ... July 30, 2015 , ... ... the right and necessity for women to ensure their children have the nutrition ... of children from pre-birth by offering discount cards for many prescription pre-natal vitamins. ...
(Date:7/29/2015)... , ... July 30, 2015 , ... ... for their clients, BOC approved provider of online continuing education courses for ... offerings to their exclusive Andrews Research and Education Sports Medicine Series. , The ...
(Date:7/29/2015)... Mary, FL (PRWEB) , ... July 29, 2015 , ... ... Healthcare Providers and Systems (CAHPS) for PQRS Survey. , The CAHPS for PQRS ... In 2015, practices of 100 or more eligible providers must participate or they will ...
Breaking Medicine News(10 mins):Health News:The Vision Enhancing “Bionic Eye” Deemed Safe For Long Term Use After Three Year Clinical Trial 2Health News:SRO Surgeon Dr. Nathan Ehmer Backs Up Latest Study That Total Hip Replacement Surgery Patients Are Resuming Normal Activities Sooner 2Health News:SRO Surgeon Dr. Nathan Ehmer Backs Up Latest Study That Total Hip Replacement Surgery Patients Are Resuming Normal Activities Sooner 3Health News:Medicationdiscountcard.com Encourages Pre-Natal Wellness in Time for World Breast-Feeding Week 2Health News:Medicationdiscountcard.com Encourages Pre-Natal Wellness in Time for World Breast-Feeding Week 3Health News:Medicationdiscountcard.com Encourages Pre-Natal Wellness in Time for World Breast-Feeding Week 4Health News:Elite Online Continuing Education Provider Adds Six New Athletic Training Courses to Exclusive Andrews Research and Education Sports Medicine Series 2Health News:Elite Online Continuing Education Provider Adds Six New Athletic Training Courses to Exclusive Andrews Research and Education Sports Medicine Series 3Health News:Avatar Solutions Approved to Administer CAHPS for Physician Quality Reporting System (PQRS) 2Health News:Avatar Solutions Approved to Administer CAHPS for Physician Quality Reporting System (PQRS) 3
... in Bangladesh and other parts of Asia have been poisoned ... leached naturally from sediments, and now being tapped by shallow ... wells have been sunk 500 feet or more to purer ... out, contaminated water might filter down to replace it. Now, ...
... 11 October 2011 Alzheimer,s disease (AD) is a ... world. A new supplement to the Journal ... shows that multiple imaging systems are now available to ... "Alzheimer,s disease is now seen as a continuum ...
... is some evidence about the potential value of cognitive rehabilitation ... it is not sufficient to develop definitive guidelines on how ... CRT will work best for a particular patient, says a ... Research has yielded promising data on the effectiveness of some ...
... According to a study published in the October issue of ... phyllodes tumors rare breast malignancies accounting for 0.5 to ... more prevalent in Hispanic patients. Population-based estimates indicate that the ... women, with the highest frequencies in Hispanic women. Previous ...
... Lung cancer patients could receive safer and more efficient ... the University of Strathclyde in Glasgow. The scientists ... to patients through a nebuliser, rather than the current ... the treatment far more quickly than existing methods and ...
... ingredient ticagrelor can be prescribed in Germany in addition ... patients with acute ischaemia of the cardiac muscle. The ... (IQWiG) has now examined whether ticagrelor offers advantages to ... conventional drugs. This is the first co-called "early benefit ...
Cached Medicine News:Health News:Natural processes can limit spread of arsenic in water, says study 2Health News:Advances in brain imaging can expedite research and diagnosis in Alzheimer's disease 2Health News:Advances in brain imaging can expedite research and diagnosis in Alzheimer's disease 3Health News:Evidence points to potential roles for cognitive rehabilitation therapy in treating traumatic brain injury, but further research needed 2Health News:Evidence points to potential roles for cognitive rehabilitation therapy in treating traumatic brain injury, but further research needed 3Health News:Hispanic women have higher incidence of rare breast tumor 2Health News:Inhaler treatment for lung cancer 2Health News:Ticagrelor: Considerable added benefit for specific patients 2Health News:Ticagrelor: Considerable added benefit for specific patients 3Health News:Ticagrelor: Considerable added benefit for specific patients 4
(Date:7/29/2015)... BERKELEY, Calif. , July 29, 2015 /PRNewswire/ ... of the Daiichi Sankyo Group, announced today that ... clinical trial results demonstrating that the investigational drug, PLX3397, ... in most patients with tenosynovial giant cell tumor (TGCT), ... tendon sheath. Following phase 1 dose-escalation, which ...
(Date:7/29/2015)... July 29, 2015  STAAR Surgical Company (NASDAQ: STAA ... and delivery systems for the eye today reported financial results ... Second Quarter Overview , Net Sales of $18.7 ... Unfavorable Currency Impact of $2.1 Million from the Weakening Euro ... and 13% in China , APAC Sales Down 1% ...
(Date:7/29/2015)... 2015  Vanda Pharmaceuticals Inc. (Vanda) (NASDAQ: VNDA ... second quarter ended June 30, 2015. "We ... and Fanapt" said Mihael H. Polymeropoulos M.D., Vanda,s President ... cycle management of our products set the stage for ... Financial Highlights , Total net product sales ...
Breaking Medicine Technology:Daiichi Sankyo and Plexxikon Announce Study Published in NEJM Demonstrates PLX3397 Induced Prolonged Tumor Regression in Tenosynovial Giant Cell Tumor (TGCT) in Most Patients 2Daiichi Sankyo and Plexxikon Announce Study Published in NEJM Demonstrates PLX3397 Induced Prolonged Tumor Regression in Tenosynovial Giant Cell Tumor (TGCT) in Most Patients 3Daiichi Sankyo and Plexxikon Announce Study Published in NEJM Demonstrates PLX3397 Induced Prolonged Tumor Regression in Tenosynovial Giant Cell Tumor (TGCT) in Most Patients 4Daiichi Sankyo and Plexxikon Announce Study Published in NEJM Demonstrates PLX3397 Induced Prolonged Tumor Regression in Tenosynovial Giant Cell Tumor (TGCT) in Most Patients 5STAAR Surgical Reports Second Quarter 2015 Results 2STAAR Surgical Reports Second Quarter 2015 Results 3STAAR Surgical Reports Second Quarter 2015 Results 4STAAR Surgical Reports Second Quarter 2015 Results 5STAAR Surgical Reports Second Quarter 2015 Results 6STAAR Surgical Reports Second Quarter 2015 Results 7STAAR Surgical Reports Second Quarter 2015 Results 8STAAR Surgical Reports Second Quarter 2015 Results 9STAAR Surgical Reports Second Quarter 2015 Results 10STAAR Surgical Reports Second Quarter 2015 Results 11STAAR Surgical Reports Second Quarter 2015 Results 12STAAR Surgical Reports Second Quarter 2015 Results 13STAAR Surgical Reports Second Quarter 2015 Results 14STAAR Surgical Reports Second Quarter 2015 Results 15STAAR Surgical Reports Second Quarter 2015 Results 16STAAR Surgical Reports Second Quarter 2015 Results 17STAAR Surgical Reports Second Quarter 2015 Results 18STAAR Surgical Reports Second Quarter 2015 Results 19STAAR Surgical Reports Second Quarter 2015 Results 20STAAR Surgical Reports Second Quarter 2015 Results 21STAAR Surgical Reports Second Quarter 2015 Results 22STAAR Surgical Reports Second Quarter 2015 Results 23STAAR Surgical Reports Second Quarter 2015 Results 24Vanda Pharmaceuticals Reports Second Quarter 2015 Financial Results 2Vanda Pharmaceuticals Reports Second Quarter 2015 Financial Results 3Vanda Pharmaceuticals Reports Second Quarter 2015 Financial Results 4Vanda Pharmaceuticals Reports Second Quarter 2015 Financial Results 5Vanda Pharmaceuticals Reports Second Quarter 2015 Financial Results 6Vanda Pharmaceuticals Reports Second Quarter 2015 Financial Results 7Vanda Pharmaceuticals Reports Second Quarter 2015 Financial Results 8Vanda Pharmaceuticals Reports Second Quarter 2015 Financial Results 9
Myoglobin RIA Lipid / Protein Quantification, Cardiovascular 024-IDC-11 Muscle Disease...
ACTH EIA Hypertension / Cardiac Evaluation, Cardiovascular 021-SDX018...
Anti-Gliadin IgG (Ab) EIA Gastrointestinal Markers 027-GD16 Celiac Disease Food Allergy...
... D kit is an enzymeimmunoassay for the ... metabolites in serum or plasma. Calibrators, controls ... 25-OH D. The diluted samples are incubated ... a highly specific sheep 25-OH D antibody ...
Medicine Products: